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Abstract: Lung-targeting drugs are thought to be potential therapies of refractory lung diseases 
by maximizing local drug concentrations in the lung to avoid systemic circulation. However, 
a major limitation in developing lung-targeted drugs is the acquirement of lung-specific ligands. 
Pulmonary surfactant protein A (SPA) is predominantly synthesized by type II alveolar epithelial 
cells, and may serve as a potential lung-targeting ligand. Here, we generated recombinant rat 
pulmonary SPA (rSPA) as an antigen and immunized an alpaca to produce two nanobodies 
(the smallest naturally occurring antibodies) specific for rSPA, designated Nb6 and Nb17. 
To assess these nanobodies’ potential for lung targeting, we evaluated their specificity to lung 
tissue and toxicity in mice. Using immunohistochemistry, we demonstrated that these anti-rSPA 
nanobodies selectively bound to rat lungs with high affinity. Furthermore, we intravenously 
injected fluorescein isothiocyanate-Nb17 in nude mice and observed its preferential accumulation 
in the lung to other tissues, suggesting high affinity of the nanobody for the lung. Studying acute 
and chronic toxicity of Nb17 revealed its safety in rats without causing apparent histological 
alterations. Collectively, we have generated and characterized lung-specific nanobodies, which 
may be applicable for lung drug delivery.
Keywords: nanobodies, rSPA, phage-nanobody library, V
HH
, lung-targeting drugs
Introduction
Development of lung-targeting ligands has been an important focus of drug delivery 
for the treatment of respiratory diseases to increase drug concentrations in the lung 
and minimizing toxicity. Currently, two major forms of lung-targeting drugs have 
been developed: 1) inhaled drugs, which are directly delivered to the respiratory tract, 
thereby improving pharmacological effects of therapy and minimizing unwanted 
systemic side effects (such as inhaled broncholytics, inhaled anti-inflammatory 
drugs, and inhaled vasodilators)1–3 and 2) passive lung-targeting drugs, which are 
likely localized in pulmonary capillary mechanical retention (eg, levofloxacin 
liposome).4–6 However, inhaled drugs have shown only limited efficacy against airway 
diseases, due to the barriers of respiratory structures and cooperation of patients.7 
Furthermore, clinical application of passive lung-targeting drugs is also hampered 
by the high retention of the reticuloendothelial system, such as the liver and spleen. 
Therefore, there is an urgent need to develop more effective lung-targeting drugs 
or delivery ligands.
An antibody may recognize its antigen in vivo with high affinity and specificity. 
Based on this principle, active targeting drugs that consist of antibody ligands and 
nanoparticles via chemical conjugation have increased drug concentrations in the 
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targeting tissue and decreased distribution in unrelated 
organs (especially in the liver and spleen) compared to their 
nontargeting counterparts.8–10 Because certain cancer cells 
overexpress growth-factor receptors or other molecules that 
can be easily targeted, recent studies have largely focused on 
tumor-targeting drugs.11–13 However, to date, the development 
of active lung-targeting drugs has been hampered by the lack 
of specific ligands for lung tissue.
Studies have shown that pulmonary surfactant protein 
A (SPA) is predominantly produced by alveolar epithelial 
type II cells and rarely expressed elsewhere.14 In recent 
years, SPA has become a commonly used marker of the 
lung for diagnosis of lung diseases.15,16 Therefore, SPA 
may serve as an attractive lung-targeting molecule for the 
development of active lung-targeting drugs. Particularly, 
targeting SPA by an antibody may be a viable approach. 
We have successfully developed dexamethasone lipo-
somes with active lung-targeting distribution by linking 
anti-SPA polyclonal antibodies (SPA-poly-ant) with a 
dexamethasone (DXM) nanoliposome (NLP) surface 
(SPA-DXM-NLP).17 The concentration of the SPA-DXM-
NLP complex in the lung is approximately fivefold greater 
than the free DXM control initially and reached 40-fold 
greater at 12 hours postinjection. Also, administration of 
SPA-DXM-NLP significantly attenuates lung injury in 
animal models. However, using full-size antibodies like 
anti-SPA-poly-ant for ligands is not ideal, because of their 
high molecular weight, strong immunogenicity, and low 
tissue penetration.18
To overcome this problem, recent studies have illustrated 
that the serum of Camelidae contains some special antibodies 
that are naturally devoid of light chains, termed heavy-chain 
antibodies (HcAbs).19 HcAbs can recognize their cognate 
antigens by a single variable-domain, referred to as V
HH
. 
Due to the nanometer-scale size of V
HH
, Ablynx (a company 
focusing on therapeutic applications of camelid antibodies) 
renamed V
HH
s Nanobodies® (Nbs).20,21 Nanobodies are the 
smallest naturally occurring intact antigen-binding domains 
of antibodies identified to date. In addition, benefiting from 
their small size, nanobodies are of higher affinity, more 
soluble, and more stable than other antibody fragments, such 
as F(ab’)
2
 or single-chain antibodies.22 Nanobodies also have 
better tissue penetration and less immunogenicity,23 which 
may be promising for application in the antitumor and anti-
infection fields.24–26
In this study, we report the development of novel anti-
rSPA nanobodies and the assessment of in vitro and in vivo 
targeting ability and toxicity.
Materials and methods
Materials
GenScript constructed the recombinant plasmid pGEX-4-
T-1-rSPA containing the rSPA gene sequence (Nanjing, 
People’s Republic of China [PRC]). The plasmid (pET-44a, 
pET-30a, pCANTAB5E), Escherichia coli BL21, Ex Taq 
deoxyribonucleic acid (DNA) polymerase, deoxynucleotide 
triphosphates (dNTPs), and DNA-purification kit were 
purchased from Tiangen Biotech (Beijing, PRC). A DNA 
ligation Kit, DNA markers, and restriction endonucleases 
were obtained from Takara Biotech (Dalian, PRC). Our 
laboratory prepared the rabbit antialpaca IgG antibody. 
Isopropyl-β-d-thiogalactoside (IPTG), horseradish per-
oxidase (HRP)-conjugated goat antirat IgG, and anti-His 
monoclonal antibody were provided by Beijing Biosynthesis 
Biotechnology (Beijing, PRC). Quartz crystal microbalance 
(QCM) measurements were performed using a Q-Sense D300 
instrument with 5 MHz quartz crystals deposited with gold 
electrodes (14 mm diameter) on a single side of the surface 
(Q-Sense, Gothenburg, Sweden). All other reagents were 
at least analytical grade for this study, and were purchased 
from Sigma-Aldrich (St Louis, MO, USA).
animals
BALB/c-nu/nu female mice, approximately 4 weeks old and 
18–20 g, were housed in specific pathogen-free conditions. 
Female Sprague Dawley rats, approximately 4–5 weeks old 
and 100±10 g, were purchased from Shanghai SLAC Labo-
ratory Animal Co Ltd (laboratory animal production license 
SCXK [Hu]). The Institutional Animal Ethics Committee for 
Experimentation on Animals of Tongji University approved 
all animal experiments.
Preparation of rsPa antigen
A 245 bp fragment of the rSPA gene (verified via the National 
Center for Biotechnology Information website) was optimized 
based on E. coli codon usage, synthesized by GenScript, 
and subcloned into the pET-44a expression vector. Then, 
the recombinant plasmid pET-44a-rSPA was transformed 
into BL21(DE3) E. coli bacteria. The transformants were 
inoculated in Lysogeny broth medium containing 70 μg/mL 
ampicillin and incubated overnight at 37°C/250 rpm. 
Expression was induced with different concentrations of 
IPTG (0.5, 0.8, and 1 mM) in various induction times and 
temperatures (2, 4, and 8 hours and 25°C, 30°C, 37°C). 
The expressed protein was examined by 12% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis gel and then purified 
by 1.0 mL nickel nitrilotriacetic acid resin (Qiagen, Valencia, 
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CA, USA). Immunoblotting and enzyme-linked immunosor-
bent assay (ELISA) using anti-rSPA-poly-ant evaluated the 
purified protein, and GST protein was used as a control.
Immunization and construction of  
anti-rsPa-Vhh libraries
Immunization and construction of anti-rSPA V
HH
 libraries 
have been described in detail elsewhere.27–29 Briefly, a 2-year-
old male alpaca was immunized weekly subcutaneously with 
at least 2 mg rSPA antigen for a period of 5 weeks. Nodular 
masses at the subcutaneous injection sites were observed after 
each immunization to ensure that the immunization procedure 
was performed appropriately. Blood was collected from the 
jugular vein prior to each injection, and the sera were used 
to monitor the immunization process, determined by indirect 
ELISA. The serum antibody titers were determined by the 
presence of a positive result at the highest possible dilution. 
Fourteen days after the last immunization, peripheral blood 
(200 mL) was collected and lymphocytes were isolated. Then, 
ribonucleic acid (RNA) was extracted using a Pure RNA 
Isolation Kit (Roche, Nutley, NJ, USA), and complementary 
DNA (cDNA) was synthesized via a Revert Aid First-Strand 
cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania). Nested 
polymerase chain reaction was performed to amplify the V
HH
 
fragments by using primers specific for HcAbs, which were 
designed according to the constant region (C
H
2) of alpaca 
HcAbs.30 The amplified V
HH
 fragments were ligated into the 
phagemid vector pCANTAB5E after being digested with 
the SfiI restriction enzyme. Next, the ligated vector was 
subsequently transformed into TG1 E. coli cells. The V
HH
 
repertoire was expressed in phage particles after a rescue 
procedure with the helper phage M13K07.
Panning and screening of anti-rsPa-
specific nanobodies
The panning protocol was utilized as described elsewhere.27–29 
Three consecutive rounds of panning using immunotubes that 
were coated with rSPA antigen were used to enrich the anti-
rSPA-V
HH
 libraries. Individual colonies that were specific for 
rSPA after the third round of panning were tested in a phage 
ELISA. Briefly, clones were grown in 2× YT medium with 
100 μg⋅mL−1 ampicillin and 0.1% glucose medium. They 
were then infected with M13K07 helper phage and incubated 
at 37°C for 30 minutes. Then, 50 μg⋅mL−1 kanamycin was 
added and the clones amplified overnight at 37°C with 
shaking. The cultured clones were next centrifuged, and 
100 μL of supernatant containing the recombinant phage 
particles was then added to rSPA precoated microtiter plate 
wells. After 2 hours’ incubation at 37°C, microtiter plate 
wells were washed three times with phosphate-buffered 
saline (PBS)-Tween 20 followed by the addition of anti-
M13 HRP conjugate (1/5,000). V
HH
 phages that were 
bound to rSPA were detected by adding 100 μL of HRP 
substrate (KPL, Gaithersburg, MD, USA). After 15 minutes 
of incubation, the reaction was stopped using 1 M H
3
PO
4
, 
and absorption at 405 nm was measured. The unique V
HH
 
genes of the clones that scored positive in phage ELISA were 
selected for sequencing analysis.
Expression and purification of nanobodies
After sequence confirmation, the clones with higher affinity 
were selected for prokaryotic expression. The production 
and purification of the selected clones was described earlier. 
Then, Western immunoblotting and ELISA confirmed the 
biological activity of the purified protein. As the expression 
vector contains His-tag, anti-His antibody was used as a 
secondary antibody. At the same time, the purified protein 
concentrations were measured by bicinchoninic acid assay.
Biophysical analyses of Nb17
First, Nb17 was adjusted to a concentration of 10 μg/mL 
in PBS. A goat anti-rSPA-poly-ant was used as control. 
Both were incubated at various temperatures (0°C, 10°C, 
30°C, 50°C, 70°C, and 100°C) and at various pH values 
(3.5, 6.5, 7.0, 7.3, 7.5, 8.0, and 8.5 for 2 hours). After incuba-
tion, Nb17 and rSPA-poly-ant were subsequently incubated 
for 30 minutes at room temperature. To test antibody binding, 
all samples were detected using the standard procedure as 
described in the following. Nb17 and rSPA-poly-ant were 
transferred to rSPA-coated microplates. After incubation for 
1 hour, microplates were blocked to reduce a specific binding 
with PBS containing 1% bovine serum albumin and 0.05% 
Tween 80. Then, Nb17 and rSPA-poly-ant was used as the 
second antibody. As the third step, goat antimouse conjugated 
with HRP was used.
Immunohistochemistry
In order to determine the binding activity of the purified anti-
rSPA nanobodies to SPA, we performed immunohistochem-
istry using the frozen sections of the lung, heart, liver, spleen, 
kidney, and muscle tissue of rats. A goat anti-rSPA-poly-ant 
was used as a positive control for the primary antibody. 
The anti-rSPA nanobodies (Nb6 and Nb17) were used for 
the experimental groups, while an unrelated nanobody was 
used as the negative-control group. The secondary antibody 
used in both the experimental and the negative-control 
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groups was mouse anti-His monoclonal antibody, and in the 
positive-control group, it was rabbit antigoat IgG.
analysis of binding ability by QcM
The binding ability of Nb17 to rSPA antigen was further 
evaluated by QCM. The frequency change (∆f) is used to 
measure the ability of protein–protein binding. The formula 
of Sauerbrey − ∆f =−2.6×105 f
0
∆M/A − proved that for 
nanobodies with gold substrate antigen binding, the better 
the quality of the greater amount of change (∆M), the greater 
the frequency, and the stronger the effect of protein binding. 
In this formula, f
0
 means quartz-oscillator base frequency 
(MHz), ∆f is frequency quartz-oscillator frequency-shift 
value of the variable (Hz), ∆M is electrode material deposited 
on the mass of the variable (g), A is the area of the working 
electrode (cm2), and a negative number represents quality. 
The procedures included 1) 0.1% mercaptopropionic acid at 
electrode surfaces to produce a carboxylic acid-terminated 
monolayer, 2) activation by 5 mg/mL ethylene dichloride and 
10 mg/mL N-hydroxysuccinimide to generate a stable acyl 
amino ester intermediate for 1 hour, and 3) adding 1 mL Nb17 
and control nanobody to gold substrates. At 37°C 1-hour 
incubation under continuous monitoring, working ranges 
from 102 to 105 cells/mL with reproducibility 10% relative 
standard deviation were obtained. The frequency change (∆f) 
indicated the ability of protein–protein binding.
Analysis of targeting efficiency in vivo
Since there was a high degree of homology (95%) in the 
amino acid sequence of SPA between the Sprague Dawley 
rats and BALB/c-nu/nu female mice and it is much easier 
to image mice, we next used nude mice (six for each group) 
for in vivo imaging. The nude mice were randomly divided 
to an experimental group (receiving Nb17) and a control 
group (receiving a goat anti-rSPA-poly-ant), which were 
labeled with fluorescein isothiocyanate (FITC). The free 
FITC group were also assigned as controls. The experimental 
group was intravenously injected with 10 μL FITC-Nb17 
(1 mg/kg), and the control group with the same amount of 
anti-rSPA-poly-ant, followed by imaging at multiple time 
points (0 and 15 minutes, and 1, 2, 3, and 6 hours) using a 
Xenogen small-animal in vivo imaging system (PerkinElmer, 
Waltham, MA, USA). For the imaging experiments, all the 
mice were first anesthetized with urethane.
acute and chronic toxicity tests
Twenty Sprague Dawley female rats were randomly divided 
into four groups: 1) the acute toxicity group, 2) the acute 
toxicity control group, 3) the chronic toxicity group, and 
4) the chronic toxicity control group. The acute toxicity 
group was intravenously injected with 10 mg/kg Nb17 and 
monitored for 1 week. The acute-negative control group 
was treated with the same volume of sterile normal saline. 
The chronic toxicity group was intravenously injected 
with Nb17 at a dose of 0.1 mg/kg Nb17 once daily for 
3 months. The chronic-negative control group was treated 
with the same volume of saline daily for 3 months. Liver 
and kidney functions were then analyzed. Tissue injury 
of rat lung, liver, spleen, and kidney tissues stained with 
hematoxylin and eosin was investigated at the indicated 
time points.
statistical analysis
All experimental data were statistically analyzed using 
SPSS 16.0 software. Continuous variables are expressed as 
mean ± standard deviation. Experimental data were ana-
lyzed by one-way analysis of variance, followed by least 
significant difference t-tests, when significant differences 
existed among groups. P-values of less than 0.05 were con-
sidered statistically significant.
Results
Preparation of antigen
The recombinant vector pET-44a-rSPA containing a 245-
amino acid fragment of SPA was created as described in the 
Materials and methods section and transformed into BL21 
E. coli. The optimum expression condition of the recombinant 
protein was found to be 0.8 mM IPTG at 37°C for 6 hours. 
The molecular weight of the expressed protein was esti-
mated to be approximately 27 kDa, suggesting a correct 
size of typical rSPA protein. Immunoblotting analysis dem-
onstrated that the expressed protein specifically bound to 
anti-rSPA polyclonal antibody at 27 kDa, whereas no band 
was seen in a control GST protein (Figure 1A). ELISA also 
showed robust binding activity between rSPA and goat anti-
rSPA-poly-ant compared to the control protein (Figure 1B). 
Overall data suggest that we successfully constructed, 
produced, and purified rSPA.
alpaca immunization, generation, and 
screening of anti-rsPa nanobody library
An alpaca was immunized with the recombinant rSPA, 
and blood serum was separated before each immunization. 
Rabbit anti-alpaca IgG labeled with HRP was prepared as a 
second antibody. Our results showed that the antibody titer 
gradually increased with increasing immunization times, 
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and reached an effective concentration of 1:12,000 after the 
fourth immunization (Table 1).
Lymphocytes were purified from 200 mL peripheral 
blood of the rSPA-immunized alpaca and total messenger 
RNA from 2.9×109 lymphocytes was extracted using Trizol 
reagent to obtain cDNA. The V
HH
 fragments with a size 
of 500 bp were generated by polymerase chain-reaction 
amplification. A V
HH
 library with 5.93×105 fragments 
was obtained. After three consecutive rounds of in vitro 
panning using the rSPA antigen, phage particles, which 
bound specifically to rSPA, were successfully enriched 
(Table 2). A total of 31 random clones with high affinity for 
rSPA were identified by phage ELISA. DNA-sequencing 
analysis revealed that six clones among them were IgG
2a
 
subtype, and 25 clones were IgG
3
 subtype (Figure 2A 
and B). Cluster analysis showed that 31 individual clones 
contained 16 different sequences, among which Nb17, 
2, and 4 contained significant repeats (identical sequences), 
and Nb12, 18, 8, and 20 and Nb6, 16, 25, and 7 contained 
another two types of repeats, which indicated significant 
enrichment of these three isotypes (Figure 2C). After 
initial testing of binding specificity for the antigen, we 
designated two of them (Nb17, Nb6) and performed further 
characterization.
Production and binding specificity of  
anti-rsPa nanobodies
Two clones, Nb6 and Nb17, were chosen for further char-
acterization. Expression conditions of both sequences were 
analyzed using various temperatures and IPTG concentra-
tions. Optimal expression levels were attained at 25°C for 
4 hours with 0.8 mM IPTG. The molecular weights of these 
proteins were approximately 19 kDa and were soluble. The 
concentration of the purified proteins was approximately 
25 mg/mL. With immunoblotting, rSPA reacted well with puri-
fied Nb6 and Nb17 with a single band of 19 kDa (Figure 3A). 
ELISA also showed that the purified Nb6 and Nb17 had 
positive reactivity to rSPA (Figure 3B).
M
27 kDa
1 2 2.5
BA
2.0
1.5
O
D
45
0
Binding activity
1.0
0.5
0
1 2
*
Figure 1 Detection of rsPa by Western immunoblot and elIsa.
Notes: (A) Western immunoblot showed the expressed rsPa (lane 2) can bind to a goat anti-rsPa polyclonal antibody compared to the negative control group (lane 1) at 27 
kDa. (B) elIsa analysis showed a high binding activity of the expressed rsPa (lane 2) to anti-rsPa polyclonal antibody compared to the negative control (lane 1). *P0.05.
Abbreviations: rsPa, rat surfactant protein a; elIsa, enzyme-linked immunosorbent assay; OD, optical density.
Table 1 alpaca immune antibody titer
Immune frequency Antibody titer
1:100 1:500 1:1,000 1:2,000 1:4,000 1:8,000 1:10,000 1:12,000
1 − − − − − − − −
2 + + + − − − − −
3 + + + + + + − −
4 + + + + + + + +
5 + + + + + + + +
Notes: + is the ratio of antibody optical density value to the negative control, optical density value greater than or equal to 2.1, and - is less than 2.1.
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To investigate further the binding ability of Nb6 and 
Nb17 to naturally occurring rSPA, immunohistochemistry 
was performed on cryosections of rat lung, heart, liver, 
spleen, kidney, and muscle. Our results showed that both Nb6 
and Nb17 preferentially bound to rat lung tissue (Figure 4, 
brown staining), but did not show binding to the heart, 
liver, spleen, kidney, or muscle, and the same-degree reac-
tion with the lung tissues by anti-SPA-poly-ant (positive 
control) was also detected. However, the binding ability of 
Nb6 was weaker than that of Nb17 and anti-SPA-poly-ant 
(Figure 4). No significant binding reaction was observed in 
the negative-control group.
Since Nb17 showed a higher binding ability to rSPA in 
immunohistochemistry than Nb6, we chose Nb17 to evaluate 
its targeting ability further. In order to investigate the biophysi-
cal feature of Nb17, a standard antigen-specific ELISA was 
performed to test whether binding could be observed at various 
temperatures and various pH values. As shown in Figure 5, 
contrary to conventional rSPA-poly-ant, Nb17 was found to 
be far more stable. In more detail, for Nb17, it is clearly shown 
that it specifically bound to rSPA even at temperatures of 
90°C and pH values of 3.5 or at 8.0. However, rSPA-poly-ant 
showed almost no antigen binding when the temperature was 
above 70°C and acid or alkaline conditions were extreme.
We next performed QCM based on the frequency change 
of quartz crystal resonance, which has been widely used to 
characterize protein features, including protein–protein inter-
action. To confirm the specific binding of Nb17 to rSPA, an 
irrelevant nanobody that did not recognize rSPA was gener-
ated and used as a negative control. As Figure 6A shows, 
the frequency change of Nb17 (∆f
17
) was significantly higher 
than that of the control nanobody (∆f
CTR
) by the passage of 
time, indicating the high binding ability between Nb17 and 
rSPA. These results suggest that our Nb17 possesses high 
specificity for rSPA.
analysis of the targeting ability of Nb17  
in mice
We chose a mouse model for in vivo imaging to detect the 
lung-targeting ability of Nb17, as rats have a high homology 
(95%) to the mouse SPA amino acid sequence. As shown in 
Figure 6B, we injected FITC-labeled Nb17 (FITC-Nb17) or 
FITC-SPA-poly-ant (control). FITC-Nb17 began to accumu-
late in mouse lungs at 15 minutes after tail-vein injection, and 
was almost completely cleared from the bladder at 6 hours 
after injection. However, no concentrated FITC was detected 
in any other organs. SPA-poly-ant also began to enter mouse 
lungs at 15 minutes after intravenous injection, but its bind-
ing to rat lungs was much lower than that of the Nb17-FITC. 
We labeled the protein according to the reaction between the 
R-amino group on lysine of protein and carbon–sulfur bond 
amine on fluorescence to form a FITC-protein conjugate 
(fluorescence antibody). A whole IgG antibody has 86 lysine 
residues, and 15–20 of them can be used for the reaction. 
As a nanobody, Nb17’s size is only 10% of an IgG antibody, 
so the overall fluorescence that can bind is much less than that 
of a whole IgG antibody. FITC-SPA-poly-ant were also seen 
in other organs at high concentration besides lungs, and almost 
completely removed from the lungs and bladder of rats at 
6 hours after injection. The free FITC group failed to show 
organ-specific accumulation, and was completely cleared 
from the kidney and the bladder of rats (data not shown).
analysis of acute and chronic toxicity
Serum alanine transaminase, aspartate transaminase, blood 
urea nitrogen, and serum creatinine were determined to assess 
the acute (1-week) and chronic (3-month) toxicity in rats as 
detailed earlier. No statistically significant differences were 
found between any of the four groups by multiple-comparison 
analysis (P0.05, Table 3). Therefore, overall data indicated 
that Nb17 had not induced significant toxicity. We further 
analyzed the histological alterations caused by Nb17 using 
cryosections of the lung, liver, spleen, and kidney in acute 
toxicity, chronic toxicity, and control groups. Our results 
showed that there were no apparent histological alterations by 
morphological assessment in tissues of the lung, liver, spleen, 
or kidney of rats between the Nb17 groups and controls using 
hematoxylin and eosin staining (Figure 7).
Discussion
Active targeting drugs are believed to have favorable 
properties, such as concentrated drugs at the site of the 
Table 2 enrichment after three rounds of panning
Panning  
round
Amount of coated  
antigen (μg/mL)
Input number  
of phages (cfu)
Output number  
of phages (cfu)
Recovery 
rate (%)
1 100 7.8×1014 4.3×105 5.5×10−7
2 50 5.3×1012 2.5×106 4.7×10−4
3 25 6.9×1012 2.1×107 3.0×10−3
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A
B
No1 (0.0925)
No29 (–0.0015)
No38 (0.0015)
No46 (0.3898)
No47 (0.2452)
No22 (0.0589)
No36 (0.0329)
No45 (0.1015)
No27 (0.0655)
No19 (0.0057)
No9 (0.0003)
No13 (0.2048)
No41 (0.1344)
No34 (0.1589)
No11 (0.0295)
No17 (0.0000)
No2 (0.0000)
No4 (0.0000)
No3 (0.0369)
No12 (0.0000)
No18 (0.0000)
No6 (0.0062)
No16 (0.0000)
No25 (0.0000)
No7 (0.0000)
No8 (0.0000)
No20 (0.0058)
No43 (0.0817)
No28 (0.0875)
No48 (0.1347)
No32 (0.1390)
C
Section 1
Section 2
Figure 2 Nanobody sequencing analysis.
Notes: (A, B) The amino acid sequences encoded by phagemid clones. all 31 sequences were Vhh sequences, in which five clones (Nb1, 43, 28, 48, 32) were an IgG2a subtype 
and the remaining clones were an Igg3 subtype. section 1 includes 1–96 amino acid sequences of all 31 sequences; section 2 includes 97–183 amino acid sequences of all 31 
sequences. (C) cluster analysis of amino acid sequences. The 31 individual clones contained 16 different sequences. among them, Nb17, 2, and 4 were repeats (with many 
identical sequences), Nb12, 18, 8, and 20 were repeats, and Nb6, 16, 25, and 7 were repeats as well. Identification of these repeats indicated the enrichment of these three 
antibody isotypes.
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Binding activity
3
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Figure 3 Analysis of the binding specificity of Nb6 and Nb17 to rSPA.
Notes: (A) Western blot showed that Nb6 (lane 1) and Nb17 (lane 2) bound to rsPa at 19 kDa, lane 3 are mark. (B) elIsa showed excellent binding activity of Nb6 (lane 1) 
and Nb17 (lane 2)to rsPa compared to the negative control (lane 3). *P0.05.
Abbreviations: rsPa, rat surfactant protein a; elIsa, enzyme-linked immunosorbent assay; OD, optical density.
Nb6
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Nb17 SPA-poly-ant Negative
Figure 4 Immunohistochemistry in vitro.
Notes: Immunohistochemistry with frozen sections of rat lungs and other organs showed that both Nb6 and Nb17 bound to the rat lung (brown coloration), but did not 
bind to the heart, liver, spleen, kidney, or muscle. The positive-control group also stained well (magnification ×200, scale bar 50 μm).
Abbreviation: sPa-poly-ant, surfactant protein a polyclonal antibody.
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Figure 5 Biophysical analyses of Nb17.
Notes: Antigen-specific ELISA was performed to test the binding ability of Nb17, SPA-poly-ant at various temperatures (A) and at various ph (B).
Abbreviations: elIsa, enzyme-linked immunosorbent assay; sPa-poly-ant, surfactant protein a polyclonal antibody.
disease, enhanced therapeutic effects, reduced systemic side 
effects, and lowered costs. However, development of active 
lung-targeting drugs has been impeded by the difficulty in 
identifying specific lung targets and their appropriate ligands. 
Thus far, studies on lung targeting have been largely depen-
dent on the mechanical retention of pulmonary capillary and 
airway inhalation, in which both have intrinsic limitations. 
To explore a new way for lung targeting, peptide targeting 
to the pulmonary vasculature was developed by screening 
phage-peptide libraries in vivo after intravenous injection into 
the lungs of mice, due to the differences in vascular endothe-
lial cells from different organs.31–33 However, this method has 
met limited success in clinical application, in part because of 
the increased risk of thrombosis. Therefore, it is necessary to 
explore a more effective lung-targeting strategy.
rSPA is one of the most abundant pulmonary surfactant 
proteins (SPs), and is expressed on alveolar epithelial type II 
cells and Clara cells. In addition, rSPA messenger RNA can 
also be detected in the epithelial cells of the middle ear, jeju-
num, colon, and serosa mesothelium, but in much lower pro-
tein levels.14 In our previous work, we also showed that rSPA 
can serve as a lung-targeting molecule. However, natural SPA 
cannot meet experimental requirements, since it is primarily 
extracted from bronchoalveolar lavage fluid, and this proce-
dure is associated with very complicated steps and a low yield. 
In this study, we generated recombinant rSPA by a prokary-
otic expression system, and successfully used the rSPA as an 
immunogen to produce lung-targeting nanobodies.
Ligands for ideal lung targeting require not only a high 
affinity to the target but also unique characteristics, including 
low molecular weight, low immunogenicity, and high tissue 
penetration. As the binding between antigen and antibody has 
high affinity and stability, anti-SPA antibody may be suitable 
for lung-targeting ligands. However, conventional antibodies 
(such as a polyclonal and monoclonal antibodies) consisting 
of two heavy and two light chains suffer from a number of 
drawbacks, such as high molecular weight (150 kDa), high 
immunogenicity, low tissue penetration, and high costs in 
production. Recent technical advances have allowed the 
transformation of those conventional antibody molecules into 
small antibody molecules (eg, Fab and single-chain variable 
fragments) through genetic engineering technology, but these 
molecules are not satisfactory for specific ligands because of 
their decreased stability and affinity to their antigens. Inter-
estingly, these drawbacks of conventional antibodies may 
be solved by using single-chain antibody fragments (V
HH
s or 
nanobodies). A nanobody is the smallest antibody molecule, 
with intact antigen-binding capability, strong stability, and 
tissue penetration. Nanobodies have been applied in multiple 
fields of medicine as a novel antibody drug.34–36 However, 
there have been no reports of any anti-rSPA nanobodies for 
lung-targeting ligands.
The ability to isolate a specific nanobody from immunized 
phage libraries has been used by several groups.27–29 In the 
present study, we successfully immunized an alpaca using 
our recombinant rSPA, and constructed a size of 5.93×105 
cfu immunized library. Fortunately, 31 clones with high 
affinity for rSPA were successfully screened using a phage 
ELISA. After DNA sequencing, 16 different V
HH
 sequences 
were obtained. Nanobodies are highly expressed in a vari-
ety of microorganisms, since they are encoded by a single 
gene, small molecular weight, and simple structure.37–40 
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Table 3 liver- and kidney-function test
Group ALT (IU/L) AST (IU/L) BUN (mmol/L) Cr (μmol/L)
acute 66.30±15.34 190.05±30.06 5.10±1.07 18.97±4.06
acute-negative 63.40±18.94 185.32±24.38 6.16±1.52 19.78±5.73
chronic 64.30±14.14 178.05±23.12 5.78±2.03 19.07±3.82
chronic-negative 65.40±13.77 188.05±24.25 6.02±1.82 20.08±4.62
Note: all values showed in the table are in mean ± sD.
Abbreviations: alT, alanine transaminase; asT, aspartate transaminase; BUN, blood urea nitrogen; cr, creatinine.
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Figure 6 Analysis of binding affinity and toxicity in the lung.
Notes: (A) Binding-ability analysis of Nb17 by quartz crystal microbalance. The maximum frequency change of Nb17 (∆f17 =190 HZ) was significantly higher than the control 
(cTr) (∆fcTr =30 HZ). This indicated that the binding specificity of Nb17 to rSPA was significantly higher than that of the control nanobody. (B) lung-targeted analysis of 
Nb17 in vivo in nude mice. The experiments were performed independently three times, and showed similar results.
Abbreviations: FITC, fluorescein isothiocyanate; rSPA, rat surfactant protein A; poly-ant, polyclonal antibody.
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Figure 7 histological analysis of rat lungs, liver, spleen, kidneys by hematoxylin and eosin staining.
Notes: Different reagents (Nb17 or control antibodies) were administered to rats for acute (1 week) or chronic (3 months) toxicity study. Then, the lung, liver, spleen, and 
kidney tissues were processed for hematoxylin and eosin staining.
Abbreviation: Neg, negative.
The methods for preparation of nanobodies are straightfor-
ward compared to the procedures for genetic engineering 
antibody preparation. The two nanobodies (Nb6 and Nb17) 
in our current study also can be routinely prepared under 
normal culture conditions, establishing a simple and efficient 
approach for nanobody preparation.
The binding ability of the nanobodies (Nb6 and Nb17) 
with rSPA was assessed and validated by immunoblotting 
and ELISA. Our data indicated that both Nb6 and Nb17 
can specifically bind to naturally occurring rSPA. Using 
immunohistochemistry, the binding ability of Nb17 was 
as strong as the positive-control group (a commercial anti-
SPA-poly-ant), while Nb6 was relatively weak. One possible 
explanation for this phenomenon is that in spite of the high 
degree of similarity between the sequences of Nb17 and Nb6, 
a tiny difference in variable region contributes enormously 
to binding strengths.
When antibodies were tested for functional binding at 
various temperatures and at various pH conditions to their 
antigen, major differences were observed between the Nb17 
and rSPA-poly-ant. It is possible that the extreme conditions 
resulted in dissociation of the polyantibody structure, thereby 
exposing the hydrophobic interfaces on both heavy and light 
chains. The exposed hydrophobic interfaces subsequently 
aggregated and precipitated, resulting in nonfunctional 
molecules. However, contrary to conventional antibodies, 
because of the efficient refolding after chemical or thermal 
denaturation of nanobodies and an additional disulfide bond 
between complementary determining regions CDR1 and 
CDR3, improved protein stability can be obtained.41,42
To determine further the lung-targeting ability of the 
recombinant nanobody, we performed in vivo imaging by 
labeling Nb17 with FITC (FITC-Nb17). FITC-Nb17 began 
to accumulate in the lung at 15 minutes after intravenous 
injection, but was completely metabolized by the kidney 
and bladder at 6 hours after injection. Compared to SPA- 
poly-ant, FITC-Nb17 had much higher accumulation and 
longer retention in the lung. Importantly, no obvious accu-
mulation of free FITC (a negative control) was detected in 
any organs. This finding strongly suggests not only strong 
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lung-targeting capability for Nb17 but also limited retention 
in the liver and spleen. Although it is impossible to have 
no cross-reactivity, background retention in those organs 
appeared to be minimal.
In addition to analyzing in vivo biodistribution, we also 
carried out acute and chronic toxicity tests with the anti-rSPA 
nanobodies. Our results confirmed the safety of the nanobod-
ies in rats, which is consistent with previous reports.43 In fact, 
the nanobodies had small molecular weights with only one 
domain and without an Fc domain of a traditional antibody, 
thus avoiding complement activation caused by the Fc domain. 
Additionally, the nanobodies bore a high degree of homology 
with the human V
H
 gene-family sequence, which may contrib-
ute to their low immunogenicity and high safety profile in the 
context of using nanobodies in future clinical therapeutics.
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